Clinical molecular imaging in intestinal graft-versus-host disease: Mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography

Blood

Volumn 111, Issue 5, 2008, Pages 2909-2918

  Stelljes, Matthias ^a   Hermann, Sven ^a   Albring, Jörn ^a   Köhler, Gabriele ^a   Löffler, Markus ^a   Franzius, Christiane ^a   Poremba, Christopher ^b   Schlösser, Verena ^a   Volkmann, Sarah ^a   Opitz, Corinna ^a   Bremer, Christoph ^a   Kucharzik, Torsten ^a   Silling, Gerda ^a   Schober, Otmar ^a   Berdel, Wolfgang E ^a   Schäfers, Michael ^a   Kienast, Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GREEN FLUORESCENT PROTEIN; DIAGNOSTIC AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COLON DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; ALLOTRANSPLANTATION; ANIMAL; CELL MOTION; COLON; DONOR; ENTEROPATHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFLAMMATION; LYMPHOCYTE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

ADULT; AGED; ANIMALS; CELL MOVEMENT; COLON; FEMALE; FLUORODEOXYGLUCOSE F18; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; INTESTINAL DISEASES; LYMPHOCYTES; MALE; MICE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 41949090993     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119164     Document Type: Article

References (54)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
2. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750- 758.
3. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
4. Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005;106:3314-3321.
5. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.
6. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156-162.
7. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109:4582-4585.
8. Fabre JW. The allogeneic response and tumor immunity. Nat Med. 2001;7:649-652.
9. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29-52.
10. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
11. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia; Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:813-818.
12. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation: IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702-3709.
13. Remberger M, Persson U, Hauzenberger D, Ringden O. An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2002;119:751-759.
14. Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002;162:1558-1566.
15. Martin PJ, McDonald GB, Sanders JE, et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10:320-327.
16. Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol. 2000;95:3034-3038.
17. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology. 1994;107: 1398-1407.
18. Wu D, Hockenberry DM, Brentnall TA, et al. Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. Transplantation. 1998;66:1319-1324.
19. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation, part I. Gas- troenterology. 1986;90:460-477.
20. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
21. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001;29:259-277.
22. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
23. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406-414.
24. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus- host disease (GVHD). Biol Blood Marrow Transplant. 2006;12:936-941.
25. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-ver- sus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
26. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
27. Ross WA, Couriel D. Colonic graft-versus-host disease. Curr Opin Gastroenterol. 2005;21:64-69.
28. Takatsuka H, Iwasaki T, Okamoto T, Kakishita E. Intestinal graft-versus-host disease: mechanisms and management. Drugs. 2003;63:1-15.
29. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130:394-403.
30. Fallows G, Rubinger M, Bernstein CN. Does gas- troenterology consultation change management of patients receiving hematopoietic stem cell transplantation? Bone Marrow Transplant. 2001; 28:289-294.
31. Ponec RJ, Hackman RC, McDonald GB. Endo- scopic and histologic diagnosis of intestinal graft- versus-host disease after marrow transplantation. Gastrointest Endosc. 1999;49:612-621.
32. Stelljes M, Strothotte R, Pauels HG, et al. Graft- versus-host disease after allogeneic hematopoi- etic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood. 2004;104:1210-1216.
33. Stelljes M, Specht C, Albring J, et al. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen- targeted GvT effects. Transplantation. 2007;83:314-322.
34. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood. 1996;88: 3230-3239.
35. Schafers KP, Reader AJ, Kriens M, Knoess C, Schober O, Schafers M. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med. 2005;46:996-1004.
36. Dutt S, Ermann J, Tseng D, et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood. 2005;106:4009-4015.
37. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2007; prepublished online November 7, 2007 as DOI 10.1182/blood-2007-09- 112789.
38. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106:1113-1122.
39. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4 + CD25+ regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220-2226.
40. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
41. Nagler A, Ohana M, Alper R, et al. Induction of oral tolerance in bone marrowtransplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model. Bone Marrow Transplant. 2003;32:363-369.
42. Bombi JA, Nadal A, Carreras E, et al. Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease. Am J Clin Pathol. 1995;103:690-695.
43. Schulenburg A, Turetschek K, Wrba F, et al. Early and late gastrointestinal complications after my- eloablative and nonmyeloablative allogeneic stem cell transplantation. Ann Hematol. 2004;83: 101-106.
44. Roy J, Snover D, Weisdorf S, Mulvahill A, Filipovich A, Weisdorf D. Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease. Transplantation. 1991;51:642-646.
45. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S, McGlave P. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol. 1985;16:387-392.
46. Thompson B, Salzman D, Steinhauer J, Lazenby AJ, Wilcox CM. Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: determination of the best diagnostic approach. Bone Marrow Transplant. 2006;38:371-376.
47. Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97:1978-1985.
48. Mentzel HJ, Kentouche K, Kosmehl H, et al. US and MRI of gastrointestinal graft-versus-host disease. Pediatr Radiol. 2002;32:195-198.
49. Kalantari BN, Mortele KJ, Cantisani V, et al. CT features with pathologic correlation of acute gastrointestinal graft-versus-host disease after bone marrow transplantation in adults. Am J Roentgenol. 2003;181:1621-1625.
50. Klein SA, Martin H, Schreiber-Dietrich D, et al. A new approach to evaluating intestinal acute graft- versus-host disease by transabdominal sonography and colour Doppler imaging. Br J Haematol. 2001;115:929-934.
51. Coy DL, Ormazabal A, Godwin JD, Lalani T. Imaging evaluation of pulmonaryand abdominal complications following hematopoietic stem cell transplantation. Radiographics. 2005;25:305-317.
52. Cauchon N, Langlois R, Rousseau JA, et al. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007;34:247-258.
53. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis. 2006;11:2089-2101.
54. Faust A, Wagner S, Law MP, et al. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2- [18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxym- ethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging. 2007;51:67-73.